A MARKET LEADER FOR PARENTERAL EXCIPIENTS
Gene therapy solutions and pharmaceutical biomaterials
As a fully integrated solutions provider for advanced drug delivery, Evonik can support you at any stage of the drug development process, including manufacturing of pharmaceutical excipients, developing innovative formulations, as well as the production of clinical drug product through commercial quantities. We build on more than six decades of experience in the development, manufacture, and supply of bioresorbable polymers as parenteral excipients. Our pharmaceutical biomaterials, including controlled release and long-acting injectable formulations, are used by customers worldwide across a wide range of drug types, therapies and application areas. We also offer a comprehensive parenteral drug delivery portfolio of gene therapy solutions such as PhytoChol® plant-derived cholesterol, lipids and (LNP)-/ liposome-based formulations.
AN INTEGRATED PORTFOLIO OF PHARMACEUTICAL BIOMATERIALS AND CUSTOM POLYMER SYNTHESIS SERVICES
Evonik develops and supplies the pharmaceutical biomaterial brands RESOMER® and LACTEL®. These polymers are fully bioresorbable and completely metabolized by the body, ideal for terminal sterilization and with a shelf life exceeding five years. Both RESOMER® and LACTEL® are highly suitable for use with small molecules, peptides, proteins, and other substances. Our bioresorbable polymers are supplied from multiple established manufacturing sites in the U.S. and Germany, providing extensive options for dual sourcing or optimizing supply security. In addition to the development and supply of our own pharmaceutical biomaterial brands such as RESOMER® and LACTEL® we can also support customers in the custom synthesis of their own proprietary polymers at our manufacturing sites in the U.S. and Germany.
Looking for information compiled in one document? Our brochures offer an overview of relevant details in just a few pages.
A GLOBAL CDMO FOR LIPID NANOPARTICLES, PROVIDING FORMULATION AND PROCESS DEVELOPMENT FOR MRNA AND GENE THERAPIES
Therapies using a range of nucleic acids have great potential to treat cancer, metabolic or infectious diseases. Specialized contract development and manufacturing partners with a high degree of flexibility will play a crucial role in supporting the pharmaceutical industry to realize the potential of gene therapies and their future applications. Evonik has a portfolio of solutions to meet the demand for mRNA and gene delivery. This includes a supply of plant-derived cholesterol PhytoChol®, custom lipid solutions from process development through commercial manufacturing at any scale for the lipid you need, and end-to-end lipid nanoparticle (LNP) formulation services. To unleash the potential of gene therapies, drug developers can count on the support of Evonik Health Care as a trusted and experienced provider of high-quality functional excipients and contract development and manufacturing services who understands how to overcome biological barriers and optimize new and emerging drugs.